Metropolis Healthcare Ltd.
NSE: METROPOLIS · Healthcare Service Provider
Snapshot
Unlock Metropolis Healthcare Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Metropolis Healthcare Limited is a diagnostic service provider offering clinical laboratory testing and pathology services across India. The company provides a comprehensive range of diagnostic solutions for various medical specialties, including oncology, neurology, and nephrology, alongside corporate wellness and clinical research services.
Business Model
The company generates revenue through diagnostic testing services delivered via a network of clinical laboratories, pick-up points, and assisted referral centres. It serves individual patients, corporate clients, and hospitals through both routine and specialised health check-up packages.
- Clinical Laboratories:171
- Pick-up Points:9,000
- Assisted Referral Centres:704
Growth Outlook
Growth is driven by the expansion of its diagnostic network and the increasing demand for specialised testing and preventive health check-ups. The company continues to leverage its established infrastructure to capture market share in both retail and institutional segments.
Key Risks
- Regulatory Risk. Changes in government regulations regarding diagnostic pricing and quality standards could impact profit margins.
- Competitive Intensity. The diagnostic sector in India is highly fragmented and competitive, with significant pressure from both large chains and local players.
- Operational Risk. Maintaining consistent service quality and turnaround times across a vast network of laboratories and collection centres is critical to brand reputation.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Metropolis Healthcare Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,646 Cr
TTM · consolidated
NET PROFIT
₹191 Cr
TTM · consolidated
EPS
₹29.32
TTM · consolidated
RETURN ON EQUITY
13.9%
TTM · consolidated
P/E
19.7x
Q4 FY26 · consolidated
EV/EBITDA
28.0x
Q4 FY26 · consolidated
EBITDA MARGIN
25.9%
TTM · consolidated
NET PROFIT MARGIN
12.0%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Healthcare Service Provider
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Metropolis Healthcare Ltd.METROPOLIS | 9,100 | 19.73 | 28.04 | 23.6% | 25.9% | 13.9% | 17.4% | -70.8% |
Vijaya Diagnostic Centre Ltd.VIJAYA | 9,130 | 83.93 | 40.52 | 19.5% | 43.9% | 20.7% | 22.6% | +37.3% |
Thyrocare Technologies Ltd.THYROCARE | 5,857 | 24.86 | 9.89 | 20.6% | 33.7% | 29.3% | 36.5% | -56.0% |
Nephrocare Health ServicesNEPHROPLUS | 5,259 | — | — | — | 22.0% | — | — | — |
Krsnaa Diagnostics Ltd.KRSNAA | 1,832 | 17.47 | 8.92 | 7.8% | 33.0% | 11.2% | 14.7% | -34.5% |
Suraksha Diagnostic Ltd.SURAKSHA | 1,318 | 41.25 | 13.66 | — | 32.1% | 14.7% | 18.4% | -19.9% |
As of Q4 FY26
Financials
Metropolis Healthcare Ltd.
NSE: METROPOLIS · Healthcare Service Provider
Snapshot
Unlock Metropolis Healthcare Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Metropolis Healthcare Limited is a diagnostic service provider offering clinical laboratory testing and pathology services across India. The company provides a comprehensive range of diagnostic solutions for various medical specialties, including oncology, neurology, and nephrology, alongside corporate wellness and clinical research services.
Business Model
The company generates revenue through diagnostic testing services delivered via a network of clinical laboratories, pick-up points, and assisted referral centres. It serves individual patients, corporate clients, and hospitals through both routine and specialised health check-up packages.
- Clinical Laboratories:171
- Pick-up Points:9,000
- Assisted Referral Centres:704
Growth Outlook
Growth is driven by the expansion of its diagnostic network and the increasing demand for specialised testing and preventive health check-ups. The company continues to leverage its established infrastructure to capture market share in both retail and institutional segments.
Key Risks
- Regulatory Risk. Changes in government regulations regarding diagnostic pricing and quality standards could impact profit margins.
- Competitive Intensity. The diagnostic sector in India is highly fragmented and competitive, with significant pressure from both large chains and local players.
- Operational Risk. Maintaining consistent service quality and turnaround times across a vast network of laboratories and collection centres is critical to brand reputation.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Metropolis Healthcare Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,646 Cr
TTM · consolidated
NET PROFIT
₹191 Cr
TTM · consolidated
EPS
₹29.32
TTM · consolidated
RETURN ON EQUITY
13.9%
TTM · consolidated
P/E
19.7x
Q4 FY26 · consolidated
EV/EBITDA
28.0x
Q4 FY26 · consolidated
EBITDA MARGIN
25.9%
TTM · consolidated
NET PROFIT MARGIN
12.0%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Healthcare Service Provider
As of Q4 FY26